MAXCYTE INC.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 143
- Market Cap
- $454.1M
- Website
- http://www.maxcyte.com
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
Phase 1
Terminated
- Conditions
- Peritoneal MesotheliomaAdenocarcinoma of the OvaryPrimary Peritoneal CarcinomaFallopian Tube Adenocarcinoma
- Interventions
- Biological: MCY-M11Drug: Cyclophosphamide
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- MaxCyte, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03608618
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States
🇺🇸Washington University at St. Louis, Saint Louis, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath